Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
IGM Biosciences ( (IGMS) ) has issued an update.
On August 14, 2025, IGM Biosciences completed a merger with Concentra Biosciences, resulting in IGM becoming a wholly owned subsidiary of Concentra. This merger, which followed a successful tender offer for IGM’s outstanding shares, led to the delisting of IGM from Nasdaq and the termination of its registration under the Securities Exchange Act, marking a significant shift in the company’s market presence and operational structure.
The most recent analyst rating on (IGMS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on IGM Biosciences stock, see the IGMS Stock Forecast page.
Spark’s Take on IGMS Stock
According to Spark, TipRanks’ AI Analyst, IGMS is a Neutral.
IGM Biosciences’ overall stock score is primarily impacted by its precarious financial health, characterized by high leverage and ongoing losses. While the merger with Concentra Biosciences offers potential strategic benefits, the company’s technical indicators and valuation suggest caution. The Nasdaq non-compliance notice and lease termination further highlight operational challenges.
To see Spark’s full report on IGMS stock, click here.
More about IGM Biosciences
IGM Biosciences operates in the biotechnology industry, focusing on the development of innovative therapies for cancer treatment. The company is known for its proprietary IgM antibody technology, which aims to enhance the efficacy of cancer immunotherapy.
Average Trading Volume: 637,203
Technical Sentiment Signal: Sell
Current Market Cap: $80.57M
Learn more about IGMS stock on TipRanks’ Stock Analysis page.